Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 4
2008 2
2012 1
2016 1
2017 2
2018 3
2019 2
2020 3
2021 4
2022 5
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
A long history of dense deposit disease.
Cunningham A, Kotagiri A. Cunningham A, et al. Among authors: kotagiri a. BMC Ophthalmol. 2018 Sep 14;18(Suppl 1):228. doi: 10.1186/s12886-018-0853-8. BMC Ophthalmol. 2018. PMID: 30255792 Free PMC article.
A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration: PRECISE Study Report 1.
Chorev M, Haderlein J, Chandra S, Menon G, Burton BJL, Pearce I, McKibbin M, Thottarath S, Karatsai E, Chandak S, Kotagiri A, Talks J, Grabowska A, Ghanchi F, Gale R, Hamilton R, Antony B, Garnavi R, Mareels I, Giani A, Chong V, Sivaprasad S. Chorev M, et al. Among authors: kotagiri a. J Clin Med. 2023 Apr 20;12(8):3013. doi: 10.3390/jcm12083013. J Clin Med. 2023. PMID: 37109349 Free PMC article.
A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.
Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, Ivanova MI, Loo JA, Klärner FG, Schrader T, Stahl M, Bitan G, Bronstein JM. Prabhudesai S, et al. Among authors: kotagiri a. Neurotherapeutics. 2012 Apr;9(2):464-76. doi: 10.1007/s13311-012-0105-1. Neurotherapeutics. 2012. PMID: 22373667 Free PMC article.
Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel.
Bailey C, Cackett P, Kotagiri A, Mahmood S, Minos E, Narendran N, Patwardhan A, Sim DA, Morgan-Warren P, O'Neil C, Straw K. Bailey C, et al. Among authors: kotagiri a. Eye (Lond). 2023 Jun;37(9):1916-1921. doi: 10.1038/s41433-022-02264-3. Epub 2022 Oct 7. Eye (Lond). 2023. PMID: 36207506 Free PMC article.
Consent for cataract surgery: a patient perspective.
Kotagiri AK, Khandwala M, Sundaram V, Kon C. Kotagiri AK, et al. J Cataract Refract Surg. 2008 Aug;34(8):1227-8; author reply 1228-9. doi: 10.1016/j.jcrs.2008.05.022. J Cataract Refract Surg. 2008. PMID: 18655958 No abstract available.
36 results